Highlights from the SWG

Events

Participation in the 19th European LeukemiaNet (ELN) Symposium

Location and date

This event was held in Mannheim, Germany, on April 18, 2023.

Chairs

  • D. Hoelzer
  • S. Chiaretti

Topics

  • Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands).
  • Inotuzumab ozogamicin in MRD+ ALL (G. Marconi, Italy).
  • Blina-Venetoclax in R/R or MRD+ ALL (C. Baldus, Germany).
  • Real-life use of Venetoclax-Navitoclax (F. Malfona, Italy).
  • Update of the D-ALBA Trial (S. Chiaretti, Italy).
  • Allo-SCT in CR1, part. in Ph+/Ph-like ALL (J. Ribera, Spain).
  • Progress on T-ALL: GMALL Experience (N. Gökbuget, Germany).

EWALL Meeting

Location and date

This event was held in Krakow, Poland, on June 23–24, 2023.

Chairs

  • Sebastian Giebel
  • Anna Czyżs

Program—Friday, June 23, 2023

15:00–15:10
Welcome Day 1 (Sebastian Giebel, Poland).

15:10–15:30
EWALL Organization Issues (chair: Adele Fielding).

15:30–17:00
National adult ALL studies (chair: Sebastian Giebel, Poland):

  • Upfront Blinatumomab in First Line Therapy of ALL – First Results of Phase 2 HOVON 146 Study (Anita Rijneveld, Holland)
  • Frontline Consolidation with Blinatumomab for High-Risk Ph(-) ALL. Update of the Graall-2014-QUEST study (Nicolas Boissel, France)
  • UKALL60+ trial in older persons (Adele Fielding, UK)
  • Obinutuzumab versus Rituximab for adults with ALL (OVERALL PALG ALL7 trial) (Sebastian Giebel, Poland)
  • Impact of dose modifications of PEG Asparaginase on the results of the ALL2019 trial. Interim analysis (Anna Torrent, Spain)
  • Analysis of MRD-oriented alloHSCT vs. early alloHSCT for adult KMT2A ALL (Jordi Ribera, Spain)
  • Comparison of results of ALLHR 03+ALLHR11 trials vs. those of ALL2019 trial on T-ALL according to RAS mutations (Eulalia Genescà, Spain)

17:15–18:15
Ongoing and Future Collaborative Projects (chair: Philippe Rousselot):

  • New EWALL INO2 proposal (Philippe Rousselot, France)
  • Status of the HARMONY & HARMONY+ Projects (Jordi Ribera, Spain)
  • Brexucabtagene autoleucel for the treatment of adults with R/R ALL. Experience from clinical practice (panel discussion)

Program—Saturday, June 24, 2023

08:50–09:00
Welcome Day 2 (Anna Czyż, Poland).

09:00–10:15
R/R ALL - approaches to personalized treatment (chair: Adele Fielding):

  • Personalized treatment of R/R B-ALL using gilteritinib, everolimus or trametinib + dexamethasone. PALG GET-DEX study. (Ewa Lech-Marańda, Poland)
  • R/R T-ALL based on oncogenetic, drug testing, and targeted therapy: ALL-TARGET (Philippe Rousselot, France)
  • Ser/Thr and Tyr kinase activity profiling and panel RNA sequencing to drive treatment decisions in ALL. (Eliza Głodkowska-Mrówka, Poland)

10:30–11:30
Miscellaneous (chair: Anna Czyż, Poland):

  • GRAALL-2014 trial aiming at reducing TRM and alloHSCT based on early MRD (Nicolas Boissel, France)
  • Recent EBMT studies on alloHCT in ALL (Sebastian Giebel, Poland)

Advancements

  • Incorporation of immunotherapy in frontline therapy of adult ALL in national and in an EWALL-initiated phase 3 trial (ACCADEMIA, in preparation).
  • Multicenter EWALL phase 3 trials for adults with newly diagnosed B-cell precursor ALL and T-ALL (under development).
  • Development of an EWALL guideline for diagnosis and management of adult ALL (manuscript accepted in Blood).

Forthcoming activities

  • Development of a phase 3 trial incorporating blinatumomab in first-line therapy for young adults (18-60 yr) with Ph-negative ALL.
  • Development of a pragmatic trial for R/R T-ALL.
  • Development of a phase 3 trial incorporating BH3 mimetics in newly diagnosed young adults (18-60 yr) with T-ALL.